Lemaitre Vascular (LMAT) Misses Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
LeMaitre Q4 2016 Record Sales $23.3 mm (+14%), Op. Income $3.9 mm (+27%)
February 21, 2017 4:05 PM ESTBURLINGTON, Mass., Feb. 21, 2017 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants and services, today reported Q4 2016 results, provided guidance, and announced a 22% dividend increase to $0.055/share.
Q4 2016 Results
Record sales of $23.3mm, +14% vs. Q4 2015Operating income of $3.9mm vs. $3.1mm, +27%Net income of $2.6mm vs. $2.5mm, +3%Earnings of $0.13 per diluted share vs. $0.13EBITDA of $4.8mm vs. $4.0mm, +18%Q4 2016 sales of $23.3mm increased 14% (+11% organic) vs. Q4 2015.  XenoSure and AnastoClip led growth. Sales in the Americas were... More
